297 related articles for article (PubMed ID: 32622008)
1. Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going.
Parra-Lara LG; Martínez-Arboleda JJ; Rosso F
J Glob Antimicrob Resist; 2020 Sep; 22():680-684. PubMed ID: 32622008
[TBL] [Abstract][Full Text] [Related]
2. Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19.
Mazzitelli M; Davoli C; Scaglione V; Fusco P; La Gamba V; Matera G; Trecarichi EM; Torti C
Travel Med Infect Dis; 2020; 37():101826. PubMed ID: 32739472
[No Abstract] [Full Text] [Related]
3. Hydroxychloroquine and azithromycin as a treatment of COVID-19.
Fanin A; Calegari J; Beverina A; Tiraboschi S;
Intern Emerg Med; 2020 Aug; 15(5):841-843. PubMed ID: 32474851
[No Abstract] [Full Text] [Related]
4. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
Lebeaux D; Revest M
Travel Med Infect Dis; 2020; 36():101819. PubMed ID: 32629139
[No Abstract] [Full Text] [Related]
5. Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center.
Pothen L; Yildiz H; De Greef J; Penaloza A; Beauloye C; Belkhir L; Yombi JC
Travel Med Infect Dis; 2020; 36():101788. PubMed ID: 32540396
[No Abstract] [Full Text] [Related]
6. Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?
Popescu CP; Fischer PR
Travel Med Infect Dis; 2020; 35():101764. PubMed ID: 32485391
[No Abstract] [Full Text] [Related]
7. Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research.
Frigerio M
Int J Cardiol; 2020 Oct; 316():285-286. PubMed ID: 32473921
[No Abstract] [Full Text] [Related]
8. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.
Hor CP; Hussin N; Nalliah S; Ooi WT; Tang XY; Zachariah S; Jugindar Singh GPS; Abdul Rani R; Perumal K; Cheah WK
J Infect; 2020 Aug; 81(2):e117-e119. PubMed ID: 32474031
[No Abstract] [Full Text] [Related]
9. Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.
Rosendaal FR
Int J Antimicrob Agents; 2020 Jul; 56(1):106063. PubMed ID: 32674928
[No Abstract] [Full Text] [Related]
10. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.
Bonow RO; Hernandez AF; Turakhia M
JAMA Cardiol; 2020 Sep; 5(9):986-987. PubMed ID: 32936259
[No Abstract] [Full Text] [Related]
11. Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
Bonny A; Talle MA; Ngantcha M; Tayebjee MH
Travel Med Infect Dis; 2020; 37():101861. PubMed ID: 32889105
[No Abstract] [Full Text] [Related]
12. [Not Available].
Farfán-López M; Espinoza-Culupú A
Rev Peru Med Exp Salud Publica; 2020; 37(2):383-384. PubMed ID: 32876237
[No Abstract] [Full Text] [Related]
13. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Gautret P; Lagier JC; Parola P; Hoang VT; Meddeb L; Mailhe M; Doudier B; Courjon J; Giordanengo V; Vieira VE; Tissot Dupont H; Honoré S; Colson P; Chabrière E; La Scola B; Rolain JM; Brouqui P; Raoult D
Int J Antimicrob Agents; 2020 Jul; 56(1):105949. PubMed ID: 32205204
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA).
Dar SA; Wahid M; Haque S; Almalki SS; Akhter N
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):7923-7924. PubMed ID: 32767316
[No Abstract] [Full Text] [Related]
15. Problems with the analysis in "Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19".
Atkinson JG
Int J Infect Dis; 2020 Oct; 99():37. PubMed ID: 32738492
[No Abstract] [Full Text] [Related]
16. Flexibilization of Science, Cognitive Biases, and the COVID-19 Pandemic.
Oliveira J E Silva L; Vidor MV; Zarpellon de Araújo V; Bellolio F
Mayo Clin Proc; 2020 Sep; 95(9):1842-1844. PubMed ID: 32861327
[No Abstract] [Full Text] [Related]
17. Comment on Arshad et al.: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.
Varisco TJ; Johnson ML; Thornton D
Int J Infect Dis; 2020 Oct; 99():373. PubMed ID: 32771630
[No Abstract] [Full Text] [Related]
18. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.
Decloedt EH; Reuter H; Allwood B; Parker A; Koegelenberg CFN; Blockman M; Taljaard J
S Afr Med J; 2020 Apr; 110(5):12903. PubMed ID: 32657706
[No Abstract] [Full Text] [Related]
19. Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19.
Rosenberg ES; Holtgrave DR; Udo T
Int J Infect Dis; 2020 Oct; 99():38-39. PubMed ID: 32738483
[No Abstract] [Full Text] [Related]
20. Pharmacist's perspective on HCQ treatment of COVID-19.
Wang YL; Wang SH; Yang AY
Kaohsiung J Med Sci; 2020 Aug; 36(8):660. PubMed ID: 32533592
[No Abstract] [Full Text] [Related]
[Next] [New Search]
